Alzheimers disease is the most common form of dementia in the elderly; 450,000 people in the UK and 4.5 million people in the USA suffer with this disease. This 3rd edition of Neurobiology of Alzheimers Disease gives a comprehensive and readable introduction to the disease, from molecular pathology to clinical practice. The book is intended for readers new to the field, and it also covers an extensive range of themes for those with in-depth knowledge of Alzheimers disease. It will therefore act either as an introduction to the whole field of neurodegeneration or it will help experienced researchers to access the latest research in specialist topics. Each chapter is written by eminent scientists leading their fields in neuropathology, clinical practice and molecular neurobiology; appendices detaildisease-associated proteins, their sequences, familial mutations and known structures. It will be essential reading for students interested in neurodegeneration and for researchers and clinicians, giving a coherent and cohesive approach to the whole area of research, and allowing access at different levels. For those in the pharmaceutical industry it describes the underlying molecular mechanisms involved in the pathogenesis of Alzheimers disease and explains how current and potential therapeutics may work.
Alzheimers disease: a hundred years of investigation; The neuropathology of Alzheimers disease; Molecular genetics of Alzheimers disease; Biology and molecular neuropathology of beta-amyloid protein; The molecular basis of tau protein pathology: role of abnormal hyperphosphorylation; Protein misfolding, aggregation and fibril formation: common features of cerebral and non-cerebral amyloidosis; Apolipoprotein E, amyloid beta-peptide and Alzheimers disease; Presenilins; Multiple transgenic mouse models for Alzheimers disease; Inflammation and Alzheimers disease; Cellular targets of amyloid beta-peptide: potential roles in neuronal cell stress and toxicity; Alzheimers disease as a neurotransmitter disease; NGF family of neurotrophins and their receptors: early involvement in the progression of Alzheimers disease; Clinical assessment of Alzheimers disease; Molecular and biological markers for Alzheimers disease; Current pharmacological approaches to treating Alzheimers disease; Amyloid-based therapies; Future directions: the A-beta amyloid pathway as the target for diagnosing, preventing or treating Alzheimers disease;
Comments (0)
Your review appreciation cannot be sent
Report comment
Are you sure that you want to report this comment?
Report sent
Your report has been submitted and will be considered by a moderator.